Figure 1:

Study design, imaging, and therapy timeline. Untreated tumor-bearing (N = 5) 5TGM1/KaLwRij were imaged weekly with non-CE T2 parametric mapping and 3D CE T1-weighted MR weekly beginning two weeks post 5TGM1 tumor implantation. Untreated animals were euthanized at the onset of systemic paralysis, which occurred approximately four weeks post tumor implantation. The bortezomib treatment cohort (N = 9) was similarly implanted with 5TGM1 tumors and injected with bortezomib via intraperitoneal injection at 1 mg/kg twice a week, beginning two weeks post tumor implantation. On imaging days (e.g., day 14, 21, 28), therapy and vehicle injections were performed immediately following imaging. As with the untreated tumor-bearing cohort, each mouse was imaged weekly with non-CE T2 parametric mapping and a 3D CE T1-weighted pulse sequence.